Friday, February 26, 2021 12:45:22 PM
"The inventor of Mino-Lok is a absolute genius and one of the most respected minds in the infectious diseases and treatment of Cancer. Among the many awards and accreditations Dr. Raad has also been awarded with Ellis Island Medal of Honor which was previously given to six US Presidents.
Dr. Issam Raad, MD
Scientific Advisory Board - Citius Pharmaceuticals
Treated the very first Ebola patient in the US and is also the chair of M.D. Anderson Cancer Center’s Department of Infectious Diseases and the Endowed Distinguished Professor of Medicine. Dr. Raad is the author of the underlying patents for Mino-Lok®. And has had several renowned publications for cancer and infectious diseases,
M.D. Anderson is one of the top Cancer hospital in the world.
Dr. Raad has published over 400 scientific articles in high impact peer-reviewed journals and over 35 book chapters. Dr. Raad’s studies have been heavily cited, achieving an H-index score of 80 which is the highest among his faculty peers in Internal Medicine at MD Anderson. He holds more than 73 issued patents and 17 pending patents, most of which are already applied to patient care. Because of this, Dr. Raad ranks in the upper 1% of inventors at MD Anderson in terms of patent productivity. He co-authored CDC and IDSA Guidelines, on lntravascular Catheter-Related Infections since 2001 till now. He is also the President of the American Lebanese Medical Association (ALMA).
Dr. Raad’s innovations in prevention of bloodstream infections have been endorsed at the highest level (Category 1A) by the Centers for Disease Control and Prevention (CDC). He has been widely honored for creative research and compassionate patient care, as well as outstanding mentorship and education. In 2015, Dr. Raad received the 2015 SHEA Mentor Scholar Award in recognition of his distinguished record over the last two decades in mentoring fellows and junior faculty, most of whom have assumed leadership positions as heads of infection control and prevention programs. In 2014, Dr. Raad received the outstanding “Gerald Bodey Distinguished Professor” award to honor his accomplishments in advancing the field of infections in cancer.
I believe Mino-Lok is destined to get FDA approval,
Along with the legendary founders of Citius, Chairman developed cooper vision and cooper dentistry and brands like Oral B, Vicodin and Aveeno.
CEO is considered to be one of the top marketing minds in the antibiotics pharma industry and a former president of Roche (market cap 285 Billion)
All 4 products in their pipeline are totally unique and equally exciting, Around 400,000 women a year get breast implants, and 5% of the general population suffers from Hemorrhoids. This company is going to be huge this is just the beginning."
Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 09:26:01 PM
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:15:10 PM
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology • PR Newswire (US) • 09/05/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:35:55 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 08/16/2024 08:34:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 10:25:24 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 10:19:43 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/12/2024 09:28:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 09:25:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/12/2024 09:10:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:51:13 PM
- Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. • PR Newswire (US) • 08/12/2024 08:22:00 PM
- Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments • PR Newswire (US) • 08/12/2024 12:00:00 PM
- TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update • GlobeNewswire Inc. • 08/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:20:18 PM
- Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 08/08/2024 10:59:00 AM
- Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. • PR Newswire (US) • 08/05/2024 12:00:00 PM
- TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates • PR Newswire (US) • 07/10/2024 01:10:00 PM
- Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution • PR Newswire (US) • 05/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:05:34 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM